Coronavirus Disease-19 and Liver Injury

Authors

  • Gontar Alamsyah Siregar Department of Internal Medicine, Division of Gastroenterohepatology, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
  • Ginanda Putra Siregar Department of Surgery, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
  • Darmadi Darmadi Department of Internal Medicine, Division of Gastroenterohepatology, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
  • Riska Habriel Ruslie Department of Child Health, Faculty of Medicine, Universitas Prima Indonesia, Medan, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2020.5028

Keywords:

COVID-19, liver, SARS-CoV-2

Abstract

Coronavirus Disease (COVID)-19 is a pandemic since March 11, 2020. The total case is more than a half million worldwide. Liver injury is quite common in COVID-19 patients. Direct viral infection is possible due to the presence of angiotensin converting enzyme 2 in cholangiocytes and hepatocytes. Other proposed mechanisms are virus-induced cytopathic effects, inflammation process, hypoxia and shock, increased apoptotic activity, increased positive end expiratory effect, and drug-induced. The manifestation of liver injury is mild and transient with elevated liver enzymes, bilirubin, and gamma-glutamyl transferase levels. Deterioration of liver function can occur in subjects with COVID-19 and underlying liver injury. The management is principally supportive. Hepatoprotective drugs may be administered in severe cases.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Ge H, Wang X, Yuan X, Xiao G, Wang C, Deng T, et al. The epidemiology and clinical information about COVID-19. Eur J Clin Microbiol Infect Dis. 2020;39(6):1011-9. https://doi. org/10.1007/s10096-020-03874-z PMid:32291542

Bi Q, Wu Y, Mei S, Ye C, Zou X, Zhang Z, et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: A retrospective cohort study. Lancet Infect Dis. 2020;20:911-9. https://doi.org/10.1016/ s1473-3099(20)30287-5

Musa S. Hepatic and gastrointestinal involvement in coronavirus disease 2019 (COVID-19): What do we know till now? Arab J Gastroenterol. 2020;21(1):3-8. https://doi.org/10.1016/j. ajg.2020.03.002 PMid:32253172

Fan Z, Chen L, Li J, Cheng X, Yang J, Tian C, et al. Clinical features of COVID-19-related liver functional abnormality. Clin Gastroenterol Hepatol. 2020;18(7):1561-6. PMid:32283325

Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, et al. COVID-19: Abnormal liver function tests. J Hepatol. 2020;73(3):566-74. PMid:32298767

Ridruejo E, Soza A. The liver in times of COVID-19: What hepatologists should know. Ann Hepatol. 2020;19(4):353-8. https://doi.org/10.1016/j.aohep.2020.05.001 PMid:32425991

Cheung KS, Hung IF, Chan PP, Lung K, Tso E, Liu R, et al. Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from the Hong Kong cohort and systematic review and meta-analysis. Gastroenterology. 2020;159(1):81-95. https://doi.org/10.1053/j.gastro.2020.03.065 PMid:32251668

Chau T, Lee K, Yao H, Tsang T, Chow T, Yeung Y, et al. SARS-associated viral hepatitis caused by a novel coronavirus: Report of three cases. Hepatology. 2004;39(2):302-10. https://doi. org/10.1002/hep.20111 PMid:14767982

Xu L, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. Liver Int. 2020;40(5):998-1004. https://doi.org/10.1111/liv.14435 PMid:32170806

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. https://doi. org/10.1016/s0140-6736(20)30183-5 PMid:31986264

Feng G, Zheng KI, Yang Q, Rios RS, Targher G, Byrne CD, et al. COVID-19 and liver dysfunction: Current insights and emergent therapeutic strategies. J Clin Transl Hepatol. 2020;8(1):18-24. https://doi.org/10.14218/jcth.2020.00018 PMid:32274342

Jin X, Lian J, Hu J, Gao J, Zheng L, Zhang Y, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut. 2020;69(6):1002-9. https://doi. org/10.1136/gutjnl-2020-320926 PMid:32213556

Zhang X. Epidemiology of covid-19. N Engl J Med. 2020;382:1869-70. https://doi.org/10.1056/NEJMc2005157 PMid:32220200

World Health Organization. Coronavirus Disease (COVID-19) Outbreak Situation. Available from: http://www.covid19.who.int. [Last accessed on 2020 May 28].

Zhang C, Shi L, Wang F. Liver injury in COVID-19: Management and challenges. Lancet Gastroenterol Hepatol. 2020;5(5):428-30. https://doi.org/10.1016/S2468-1253(20)30057-1 PMid:32145190

Mao R, Qiu Y, He J, Tan J, Li X, Liang J, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(7):667-78. https://doi. org/10.1016/s2468-1253(20)30126-6 PMid:32405603

Boeckmans J, Rodrigues RM, Demuyser T, Pierard D, Vanhaecke T, Rogiers V. COVID-19 and drug-induced liver injury: A problem of plenty or a petty point. Arch Toxicol. 2020;94(4):1367- 9. https://doi.org/10.1007/s00204-020-02734-1 PMid:32266419

Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology. 2020;158(6):1831-3. https://doi.org/10.1053/j.gastro.2020.02.055 PMid:32142773

Agarwal A, Chen A, Ravindran N, To C, Thuluvath PJ. Gastrointestinal and liver manifestations of COVID-19. J Clin Exp Hepatol. 2020;10:263-5. https://doi.org/10.1016/j.jceh.2020.03.001

Gu J, Han B, Wang J. COVID-19: Gastrointestinal manifestations and potential fecal-oral transmission. Gastroenterology. 2020;158(6):1518-9. https://doi.org/10.1053/j.gastro.2020.02.054 PMid:32142785

Zhang B, Zhou Z, Qiu Y, Feng F, Feng J, Jia Y, et al. Clinical characteristics of 82 death cases with COVID-19. MedRxiv. 2020;2020;15:e0235458. https://doi. org/10.1101/2020/02.26.20028191

Huang Y, Yang R, Xu Y, Gong P. Clinical characteristics of 36 non-survivors with COVID-19 in Wuhan, China. MedRxiv. 2020;(Online ahead of print). https://doi.org/10.1101/2020.02.27.20029009

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 2020;395(10223):507-13. https://doi.org/10.1016/ s0140-6736(20)30211-7 PMid:32007143

Mohamed AA, Mohamed N, Mohamoud S, Zahran FE, Khattab RA, El-Damasy DA, et al. SARS-CoV-2: The path of prevention and control. Infect Disord Drug Targets. 2020;(Online ahead of print). https://doi.org/10.2174/1871526520666200520 112848 PMid:32433010

Sarin SK, Choudhury A, Lau GK, Zheng M, Ji D, Abd-Elsalam S, et al. Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS study (APASL COVID-19 liver injury spectrum study). Hepatol Int. 2020;4:1-11. https://doi.org/10.21203/rs.3.rs-36338/v1 PMid:32623632

Iavarone M, D’Ambrosio R, Soria A, Triolo M, Pugliese N, Poggio PD, et al. High rates of 30-day mortality in patients with cirrhosis and COVID-19. J Hepatol. 2020;(Online ahead of print). https://10.1016/j.jhep.2020.06.001

Zhang JC, Wang SB, Xue YD. Fecal specimen diagnosis 2019 novel coronavirus-infected pneumonia. J Med Virol. 2020;92(6):680-2. https://doi.org/10.1002/jmv.25742 PMid:32124995

Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020;323(18):1843-4. https://doi.org/10.1001/jama.2020.3786 PMid:32159775

Downloads

Published

2020-09-30

How to Cite

1.
Siregar GA, Siregar GP, Darmadi D, Ruslie RH. Coronavirus Disease-19 and Liver Injury. Open Access Maced J Med Sci [Internet]. 2020 Sep. 30 [cited 2022 Jul. 1];8(T1):154-7. Available from: https://oamjms.eu/index.php/mjms/article/view/5028

Most read articles by the same author(s)

1 2 3 4 > >>